Global Pemphigus Vulgaris Market

Pemphigus Vulgaris Market size was valued at USD 576.98 Mn. in 2025 and the total revenue is expected to grow at a CAGR of 8.4% through 2025 to 2032, reaching nearly USD 1014.76 Mn.

Pemphigus Vulgaris Market Overview:

The Pemphigus is a severe skin condition that causes blisters on the skin and mucous membranes. Pemphigus vulgaris is the most common kind, which causes painful sores and blisters on the skin and in the mouth. The cause of Pemphigus vulgaris is unknown. Experts believe it occurs when a person with a genetic predisposition to the disease comes into touch with an environmental trigger, such as a chemical or a medicine. Pemphigus vulgaris may go away once the trigger is eliminated in some circumstances. The Pemphigus Vulgaris Market is expected to reach at USD 1014.76 Mn. by 2032. Corticosteroids, Immunosuppressants, Biological Therapies, and Intravenous Immunoglobulin (IVIG) Therapy are some of the types of the treatments of the Pemphigus Vulgaris.To know about the Research Methodology :- Request Free Sample Report

Pemphigus Vulgaris Market Dynamics:

As biological medicines have fewer negative effects, they are becoming more popular for treating pemphigus vulgaris. Glucocorticoids, on the other hand, can cause a variety of drug-related responses. During the forecast period, the pemphigus vulgaris therapy market is expected to rise due to rising demand for Mabs.

As there are fewer options for pemphigus vulgaris treatment on the market, and non-biological medications have a variety of adverse effects, researchers are focusing on Pemphigus Vulgaris Treatment and its market. The high cost of biological drugs, as well as their scarcity, are expected to retrain the growth of the pemphigus vulgaris treatment market during the forecast period.

Several medicines, such as corticosteroids and immunosuppressants, are available worldwide to treat pemphigus vulgaris. Biological treatments, such as Rituximab, are now being examined as a new method to treating pemphigus vulgaris. Rituximab has been proven to be a first-line therapy for pemphigus vulgaris treatment in the majority of randomised, controlled clinical trials. MabThera (F. Hoffmann-La Roche Ltd) received "Breakthrough Designation" classification from the FDA in 2017 for treating pemphigus vulgaris.

The goal of pemphigus vulgaris treatment is to prevent blister development, initiate erosion repair, and reduce drug dosage to the smallest amount possible. Although there is no cure for pemphigus vulgaris, pemphigus vulgaris treatment can help prevent symptoms from worsening.

Pemphigus Vulgaris Market Segment Analysis:

Based on the Treatment, the market is segmented into Corticosteroids, Immunosuppressants, Biological Therapies, Intravenous Immunoglobulin (IVIG) Therapy, and Others. Corticosteroids treatment segment is expected to hold the largest market shares of xx% by 2032. Everything from seasonal allergies to life-threatening organ inflammation is treated with corticosteroids. This family of medicines is widely used to treat autoimmune disorders. When your immune system isn't working properly, it assaults your own organs, bones, and tissues. Corticosteroids can help to reduce inflammation and protect the body from harm. They also impact the function of white blood cells and diminish immune system activity.

A corticosteroid injection can provide immediate relief to an inflamed joint in someone with rheumatoid arthritis who is experiencing a flare. When your body doesn't produce enough cortisol, you get Addison's disease, which causes weakness and fatigue among other symptoms. Corticosteroids can compensate for this. Corticosteroids assist suppress the immune system in persons who have recently had an organ transplant, lowering the risk of the organ being rejected by the body.

The major goal of treatment is to reduce blister formation, prevent infections, and enhance blister and erosion healing. Systemic corticosteroids, usually in the form of moderate to high doses of oral prednisone or prednisolone, or pulsed intravenous methylprednisolone, are the cornerstone of medical treatment for treating the illness. Many deaths from Pemphigus Vulgaris have been avoided as a result of their use, with the mortality rate dropping from 99 percent to 5-15 percent. Although corticosteroids do not cure the condition, they do improve the patient's quality of life by lowering disease activity.

Between August 2017 and July 2018, the quantity of topical corticosteroid units sold in Spain was broken down by pharmaceutical laboratory. Merck Sharp Dohme (MSD), Italfarmaco, and Faes were the top three selling laboratories in this segment during that time, with the first selling more than 2.5 million units. Topical corticosteroids are drugs that must be prescribed by a doctor. These contain anti-inflammatory and immunosuppressive characteristics and are used to treat dermatitis, psoriasis, lichen planus, and bites, among other skin problems.

Based on the End-Users, the market is segmented into Hospitals & Clinics, Specialty Dermatology Clinics, Research & Academic Laboratories, Retailers, Pharmacy, and E-Commerce. Hospitals & Clinics segment is expected to grow rapidly at a CAGR of xx% during the forecast period 2025-2032. This is due to factors such as the rising frequency of Pemphigus Vulgaris diseases and the increased number of Pemphigus Vulgaris patients. Furthermore, the cost of pemphigus vulgaris treatment in the hospital is higher, resulting in higher market revenue.

Pemphigus Vulgaris Market Regional Insights:

North America region is expected to dominate the Pemphigus Vulgaris Market during the forecast period 2025-2032. North America region is expected to hold the largest market shares of xx% by 2032. This is due to the increased research and development for novel pemphigus vulgaris treatments, as well as developments in the healthcare sector in the North America region.

Europe region is expected to grow rapidly at a CAGR of xx% during the forecast period 2025-2032. This is due to the rising prevalence of pemphigus vulgaris in Europe.

Asia Pacific is expected to grow rapidly at a CAGR of xx% during the forecast period 2025-2032. This is due to technological advancements in the health-care industry and increased investment in life-science research in the Asia Pacific region.

The objective of the report is to present a comprehensive analysis of the Global Pemphigus Vulgaris Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The reports also help in understanding the Global Pemphigus Vulgaris Market dynamic, structure by analyzing the market segments and project the Global Pemphigus Vulgaris Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Pemphigus Vulgaris Market make the report investor’s guide.

Pemphigus Vulgaris Market Recent Industry Developments (2025–2026)

Pemphigus Vulgaris Market Scope: Inquire before buying

By Region

Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Pemphigus Vulgaris Market Key Players

1. Teva Pharmaceutical Industries
2. Novartis Pharmaceuticals
3. Hoffmann-La Roche
4. Principia Biopharma, Inc.
5. Argenx SE
6. Pfizer Inc.
7. Teligent Inc.
8. GlaxoSmithKline LLC
9. Almirall
10. Biogen Inc.
11. Syntimmune
12. Sanofi
13. Janssen Global Services
14. Genentech Inc.
15. Celltrion Inc.
16. Amgen Inc.
17. Samsung Bioepis.
18. Fresenius Kabi USA.
19. Hikma Pharmaceutical PLC.